Spots Global Cancer Trial Database for Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients
Official Title: Pyrotinib Plus Vinorelbine in Metastatic HER2-positive Breast Cancer Patients- a Multicenter Retrospective Study
Study ID: NCT04517305
Conditions
Interventions
Study Description
Brief Summary: To evaluate the patterns and treatment outcomes of pyrotinib plus vinorelbine in the real world.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Contact Details
Name: Biyun Wang, Professor
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
